Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -36.84% is 25% below its 5-year average of -29.44%, around the middle of its 5-year range (-61.46%–-4.73%).
35.37% below its 12-month average of -27.21%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.10%.
RETURN ON ASSETS (ROA)
-36.84%
RETURN ON ASSETS (ROA) AVG TTM
-27.21%
RETURN ON ASSETS (ROA) AVG 3Y
-27.53%
RETURN ON ASSETS (ROA) AVG 5Y
-29.44%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.37%
CURRENT VS 3Y AVG
-33.79%
CURRENT VS 5Y AVG
-25.15%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-14.27%
vs the sector median at left
NewAmsterdam Pharma Company N.V.
Market Cap
$2.57B
Return on Assets (ROA)
-36.84%
TTM Avg
-27.21%
3Y Avg
-27.53%
5Y Avg
-29.44%
Market Cap
$2.57B
Return on Assets (ROA)
0.00%
TTM Avg
1.47%
3Y Avg
1.04%
5Y Avg
-2.29%
Market Cap
$2.58B
Return on Assets (ROA)
-6.16%
TTM Avg
-19.77%
3Y Avg
-17.54%
5Y Avg
-23.06%
Market Cap
$2.59B
Return on Assets (ROA)
-0.24%
TTM Avg
-15.97%
3Y Avg
-8.17%
5Y Avg
-3.53%
Market Cap
$2.67B
Return on Assets (ROA)
13.04%
TTM Avg
11.11%
3Y Avg
0.70%
5Y Avg
-8.32%
Market Cap
$2.47B
Return on Assets (ROA)
-7.69%
TTM Avg
1.38%
3Y Avg
1.60%
5Y Avg
3.00%
Market Cap
$2.69B
Return on Assets (ROA)
-20.31%
TTM Avg
-7.83%
3Y Avg
-2.64%
5Y Avg
-2.82%
Market Cap
$2.69B
Return on Assets (ROA)
-23.93%
TTM Avg
-22.82%
3Y Avg
-35.57%
5Y Avg
-35.57%
Market Cap
$2.69B
Return on Assets (ROA)
-92.61%
TTM Avg
-123.47%
3Y Avg
-74.33%
5Y Avg
-62.85%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. (NAMS) | $2.57B | -36.84% | -27.21% | -27.53% | -29.44% |
| Privia Health Group, Inc. (PRVA)vs › | $2.57B | 0.00% | 1.47% | 1.04% | -2.29% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.58B | -6.16% | -19.77% | -17.54% | -23.06% |
| Neogen Corporation (NEOG)vs › | $2.59B | -0.24% | -15.97% | -8.17% | -3.53% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.67B | 13.04% | 11.11% | 0.70% | -8.32% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.47B | -7.69% | 1.38% | 1.60% | 3.00% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | -20.31% | -7.83% | -2.64% | -2.82% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.69B | -23.93% | -22.82% | -35.57% | -35.57% |
| Precigen, Inc. (PGEN)vs › | $2.69B | -92.61% | -123.47% | -74.33% | -62.85% |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 1.56% | -4.54% | -5.50% | -3.43% |
ROA
-36.8%
ROE
-41.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -26.49% |
| 2024-12-31 | -27.94% |
| 2023-12-31 | -50.98% |
| 2022-12-31 | -4.73% |
| 2021-12-31 | -61.46% |
| 2020-12-31 | -5.02% |
